{"product_id":"biomeafusion-five-forces-analysis","title":"Biomea Fusion Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBiomea Fusion faces intense supplier and regulatory pressures but benefits from differentiated R\u0026amp;D and niche oncology targets; competitive rivalry is moderate while buyer power and substitutes depend on clinical outcomes. This brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Biomea Fusion’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of specialized Contract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiomea Fusion depends on a narrow set of high-quality contract manufacturing organizations (CMOs) able to make irreversible small-molecule inhibitors to cGMP standards; industry reports show fewer than 20 CMOs globally with proven capacity for such chemistry as of 2025. The complex, hazardous synthesis for BMF-219 raises switching costs—requalification often takes 6–12 months and can cost $1–5M—giving CMOs strong pricing and scheduling leverage. A single-site supply disruption historically delays clinical timelines by 6–18 months and can increase development spend by 10–30%, so supplier concentration materially heightens operational and financial risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScarcity of highly skilled scientific personnel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe specialized nature of covalent-bonding drug discovery needs deep medicinal-chemistry and molecular-biology talent; demand is high in biotech hubs (Boston, San Diego) where median senior chemist pay hit ~$180k in 2024, so suppliers of talent exert strong bargaining power.\u003c\/p\u003e\n\u003cp\u003eCompetition for these experts drives up total compensation and stock incentives, raising SG\u0026amp;A per research head; losing senior staff would slow development of Biomea Fusion’s proprietary FUSION platform and delay pipeline milestones.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary technology and reagent providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiomea Fusion depends on specialized lab equipment and proprietary reagents from few authorized vendors; industry data shows single-supplier situations can raise input costs 5–15% and delay projects by 2–6 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical research organization dependency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs a clinical-stage company, Biomea Fusion relies on CROs to run complex global trials and ensure data integrity, and in 2025 roughly 60–70% of late-phase metabolic and oncology studies are managed by the top 5 CROs, narrowing partner options.\u003c\/p\u003e\n\u003cp\u003eIndustry consolidation—10% fewer mid-tier CROs since 2019—lets established firms push harder on pricing and timelines; publicly reported CRO gross margins of 30–40% give them leverage in contract negotiations.\u003c\/p\u003e\n\u003cp\u003eThis concentration raises Biomea’s supplier risk: longer lead times, firmer milestone payment terms, and potential cost inflation of 5–15% per trial versus using multiple smaller vendors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDependence: CROs handle core trial ops and data\u003c\/li\u003e\n\u003cli\u003eConcentration: top 5 CROs run ~60–70% of large trials\u003c\/li\u003e\n\u003cli\u003eLeverage: CRO margins 30–40% strengthen bargaining power\u003c\/li\u003e\n\u003cli\u003eImpact: trial costs\/timelines may rise 5–15%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual property and licensing partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers of foundational patents or licensed chemistries can restrict Biomea Fusion’s freedom to operate and extract high royalties or milestone fees, as seen in oncology licensing deals averaging 8–15% royalties in 2024.\u003c\/p\u003e\n\u003cp\u003eIf Biomea needs third-party IP to advance its irreversible inhibitors, licensors could demand upfronts ($1–10M) and tiered milestones, increasing project break-even by years.\u003c\/p\u003e\n\u003cp\u003eMaintaining a strong internal IP portfolio—Biomea filed 6+ patent families by 2025—reduces dependency and bargaining power of licensors.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh royalty risk: 8–15% typical\u003c\/li\u003e\n\u003cli\u003eUpfronts\/milestones: $1–10M common\u003c\/li\u003e\n\u003cli\u003eInternal patents: key defense (6+ families by 2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier Power Peaks: CMOs\/CROs, Talent \u0026amp; Licensors Drive Higher Costs \u0026amp; Delays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold strong power: \u003cbr\u003eCMO concentration (\u0026lt;20 capable globally in 2025) raises switching costs (requal 6–12 months; $1–5M) and can delay trials 6–18 months; CRO top-5 run ~60–70% late-phase studies (margins 30–40%), increasing trial costs 5–15%; talent pay (senior chemists ~$180k in 2024) and licensors (royalties 8–15%; upfronts $1–10M) further strengthen supplier leverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRisk\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;20 global; requal 6–12m; $1–5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO\u003c\/td\u003e\n\u003ctd\u003eTop-5: 60–70%; margins 30–40%; +5–15% costs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTalent\u003c\/td\u003e\n\u003ctd\u003eSenior chemist pay ~$180k (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensors\u003c\/td\u003e\n\u003ctd\u003eRoyalties 8–15%; upfronts $1–10M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Biomea Fusion that uncovers competitive drivers, supplier and buyer power, potential substitutes, and entry barriers shaping its biotech market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces one-sheet for Biomea Fusion—instantly shows competitive pressures and drug-development risks to speed strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Pharmacy Benefit Managers and private insurers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn the US, pharmacy benefit managers (PBMs) and private insurers control formulary placement and reimbursement, capturing leverage that forces drugmakers to offer large rebates; PBMs handled 80%+ of prescriptions in 2024, so Biomea Fusion must negotiate steep discounts for BMF-219 to secure preferred status. Payers typically demand rebates that can exceed 30–50% of list price for novel specialty drugs, pressuring net margins and launch pricing. If Biomea fails to lock favorable coverage and co-pay assistance, uptake and peak sales—projected at hundreds of millions to low billions for mid-stage oncology agents—could collapse. Limited formulary access would sharply curtail commercial potential and investor returns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment healthcare programs and pricing legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy late 2025 the Inflation Reduction Act gives Medicare power to negotiate prices for ~60 high-cost drugs, cutting potential BIOMEA FUSION revenue upside and creating a govt-set ceiling on pricing.\u003c\/p\u003e\n\u003cp\u003eManufacturers must show strong value per cost; evidence shows negotiated drugs saw median price cuts of ~20–40% in pilot analyses, so Biomea must justify premium pricing with clear outcomes.\u003c\/p\u003e\n\u003cp\u003eAligning with federal mandates—timelines, rebate rules, and CMS negotiation rounds—will be essential for Biomea to retain market access and revenue predictability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated hospital systems and Group Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cplarge oncology centers and hospital networks buy specialized drugs via gpos for volume discounts with us gpo purchasing covering of supplies driving price pressures they can exclude therapies lacking clear clinical or economic benefit versus incumbents lowering launch uptake. building direct payer ties offering value dossiers real-world evidence contract-ready pricing is essential to win formulary access market share.\u003e\n\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient advocacy groups and public sentiment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrganized patient advocacy groups can shift drug adoption and regulator focus in rare\/genetically defined cancers; e.g., in 2024 over 60% of FDA orphan-drug designations cited patient input, boosting trial enrollment for niche therapies.\u003c\/p\u003e\n\u003cp\u003eThey often champion new Biomea Fusion treatments but press for lower prices and wider access, which can compress net margins—patient access programs raised launch discounts by ~15% in 2023 for oncology drugs.\u003c\/p\u003e\n\u003cp\u003eTheir collective voice influences physician prescribing and legislators; advocacy-led campaigns in 2022–24 helped pass 5 state-level access laws affecting formulary and reimbursement rules.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e60%+ FDA orphan designations cite patient input (2024)\u003c\/li\u003e\n\u003cli\u003eLaunch discount pressure ≈15% for oncology (2023)\u003c\/li\u003e\n\u003cli\u003e5 state access laws influenced by advocacy (2022–24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial participant availability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn the pre-commercial phase customers are trial participants and investigators; competition for patients with KMT2A\/MLL rearrangements or NPM1-mutated AML is intense, with prevalence ~5–10% of AML (US ~2,000–3,500 patients\/year in 2024). Biomea must offer attractive protocols, site networks, and potential access programs to hit enrollment targets and meet FDA\/EMA submission timelines.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLimited pool: ~5–10% AML prevalence (~2,000–3,500 US pts\/yr, 2024)\u003c\/li\u003e\n\u003cli\u003eHigh competition: multiple Menin inhibitors in trials (2024: 4+ competitors)\u003c\/li\u003e\n\u003cli\u003eNeeds: compelling design, broad sites, patient support, rapid enrollment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRebate pressure \u0026amp; small AML pool squeeze BMF-219 upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePBMs\/insurers drive formulary\/rebate leverage (PBMs \u0026gt;80% scripts 2024), forcing 30–50%+ rebates and compressing BMF-219 net price; Medicare negotiation (IRA, ~60 drugs by 2025) caps upside. GPOs cover ~90% hospital buys, limiting hospital uptake without strong value data. Trial pool small (~2,000–3,500 US AML pts\/yr, 5–10% prevalence) so enrollment competition is fierce.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023–25 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM script share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical rebates\u003c\/td\u003e\n\u003ctd\u003e30–50%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare negotiation scope\u003c\/td\u003e\n\u003ctd\u003e~60 drugs (IRA, by 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS AML eligible pts\/yr\u003c\/td\u003e\n\u003ctd\u003e2,000–3,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eBiomea Fusion Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Porter’s Five Forces analysis of Biomea Fusion you’ll receive immediately after purchase—fully formatted, professionally written, and ready to download with no placeholders or mockups.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746829414777,"sku":"biomeafusion-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/biomeafusion-five-forces-analysis.png?v=1772192254","url":"https:\/\/growthsharematrix.com\/products\/biomeafusion-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}